The Competition Commission is investigating Hetero SA for alleged price collusion in bids for SA’s major HIV drug tender involving the TLD combination pill. – BusinessDay (19 Nov 2025)
The Health Department excluded Hetero SA from the R12.6bn tender after suspecting it colluded with Pharma-Q and Q-Sol, citing shared reliance on Hetero India, overlapping documents and indications that Hetero India influenced pricing. Hetero SA denies wrongdoing and has taken the matter to court, seeking suspension of the tender and a reassessment of its bid. Rival bidder Pharma Dynamics disputes Hetero’s claim that it was not given a chance to respond before exclusion.